The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Their participation strengthened the statistical reliability of both the liver safety results and achieved statistical relevance for both sleep and testosterone results.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The second cohort included an additional 222 individuals taking CBD produced by an additional five companies.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. This Phase 1 trial is currently testing IGC-AD1 for safety. www.igcinc.us

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Veriheal

NOVEMBER 21, 2023

Quemarr Moatamedi School: University of Montana Major/Program: Linguistics and Anthropology Innovation: Emulsion-Based Edibles: Harnessing Anti-Diabetic Cannabinoids in Diabetes Management. Quemarr presents an emulsion-based drug delivery system tailored for cannabinoids and made to tackle America’s diabetes crisis.

Research and Development 93

Research and Development Consumption Education Data 93

Cannabis Law Report

SEPTEMBER 29, 2021

The Cannabinoid Institute ?(TCI) With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. TCI was founded by Drs.

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Epilepsy 58

Epilepsy Pharmaceutical Patients Sleep 58

The Joint Blog

MARCH 16, 2020

According to a new study published in the journal Phytotherapy Research, the sustained use of marijuana in patients with chronic conditions is associated with quality of life maintenance and a lack of cognitive decline. Hair analysis was conducted to confirm the presence of cannabinoids. There were also no variations in QoL.

Patients 49

Patients Marijuana Epilepsy Treatment 49

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. ADDITIONAL INFORMATION.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

SEPTEMBER 15, 2021

Delta-8 THC is one of over 100 cannabinoids produced naturally by the cannabis plant but is not found in significant amounts in the cannabis plant. Some concerns include variability in product formulations and product labeling, other cannabinoid and terpene content, and variable delta-8 THC concentrations. brownies, gummies).

THC 105

THC Pets Events Hemp 105

The Joint Blog

JANUARY 21, 2020

Marijuana use is associated with subjective benefits in patients with Tourette Syndrome (TS), according to a new study published in the journal Cannabis and Cannabinoid Research. This study was designed to further investigate efficacy and safety of CBM in GTS and specifically compare effects of different CBM.

Patients 29

Patients Marijuana Data Treatment 29

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Otherside Farms

JANUARY 25, 2019

Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke. “The

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

The Cannigma

DECEMBER 20, 2021

Recent scientific studies suggest that different cannabinoids and other cannabis-derived molecules (e.g Researchers are still in the early stages of learning how exactly cannabinoids affect skin health, but some of the results are compelling. Since then, numerous studies have explored cannabinoid activity in the different skin layers.

Terpenes 133

Terpenes Cannabinoids Topical Research and Development 133

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

DECEMBER 16, 2019

Emerald Clinics captures clinical data from patients to generate evidence for the safety and efficacy of cannabis medicines. The company also captures clinical data from patients to generate evidence for the safety and efficacy of cannabis medicines. Marta Pascual Juanola.

Medicine 59

Medicine Data Safety Therapy 59

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JUNE 17, 2022

status as a medical cannabis program patient,” or. The bill’s protections do not extend to employees whose “position is designated as safety sensitive.” Both the use of cannabis for adults and for patients is permitted in the District of Columbia.

Safety 52

Safety Legislation Policy Cannabis 52

MMJ Recs

MARCH 16, 2024

Regulations vary significantly by jurisdiction but typically encompass licensing requirements, product safety standards, and distribution protocols. Key factors influencing market size and revenue include patient demographics, regulatory frameworks, product offerings, and pricing strategies.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

SpeedWeed

MARCH 6, 2021

THC is the main psychoactive ingredient in cannabis, but it is not the only psychoactive cannabinoid. Public safety at issue. Proponents of these THC caps—who are often the same politicians who stood against legalization and lost—contend that limiting THC levels will increase public safety. Forcing patients to purchase more.

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

APRIL 1, 2022

Aguilar has suggested that “cannabis must have similar authorization and use conditions” to those that operate in Spain with products such as morphine and has opened the door for, at one time, community pharmacies -and not just hospital ones- dispense cannabinoid-based products that the Medicines Agency may authorize.

Medicine 52

Medicine Data Safety Conditions 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

SpeedWeed

FEBRUARY 21, 2021

The human primary blood cell screens performed at MSU are state-of-the-science models for evaluating the effects of compounds on the human immune system,” said Kaminski, director of the Institute for Integrative Toxicology, Professor of Pharmacology & Toxicology, and director of MSU’s Center for Research on Ingredient Safety.

Treatment 52

Treatment Research and Development Cannabinoids Data 52

Cannabis Law Report

JANUARY 23, 2022

Multivariate analysis of overall survival and nonrelapse mortality (NRM) data has shown GVHD likelihood can be impacted by age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count (Arora et al. Implications.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

The Cannigma

OCTOBER 21, 2021

Still, many patients report that cannabis helps them to feel more in control of their symptoms, leading to important questions. While there has been little systematic research on using cannabis for ADHD, many patients with the condition report positive effects from using cannabis. Can cannabis help with ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

NOVEMBER 22, 2019

“Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. MMJ is confident that their pharmaceutical drugs will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health. ” Dosages of all CBM varied markedly.

Data 49

Data Treatment Marijuana Patients 49

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. The products leverage pharmaceutical technology to maximize performance and safety. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. Poster Number: INFO37. Poster Number: PO1326.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Can Cannabis Improve Patient Experience Post-Surgery?” . Program between St. Vaibhav Duggal . School: Texas A&M University .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Veriheal

OCTOBER 29, 2020

Science Magazine explains that the ‘harms’ refer to the adverse effects and negative impacts of cannabis consumption while the ‘endocannabinoid system’ refers to the body’s cannabinoid receptors and naturally produced endocannabinoids which the cannabis cannabinoids bind to. It also shows that three countries (the U.S,

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40